Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus.
Some patients with type 2 diabetes mellitus (T2DM) are profoundly insulin resistant and require large insulin doses to achieve optimal glycaemic control. However, large volumes of subcutaneous conventional U-100 insulin can cause discomfort at the injection site, resulting in poor concordance with insulin therapy. One therapeutic option is the use of U-500 insulin, thus reducing the insulin volume by 80%. This review will address the practical issues associated with the use of U-500, clinical efficacy and safety aspects of this concentrated insulin, which has an important role in a subgroup of patients with T2DM.
Department of Diabetes and Endocrinology, University Hospitals of Leicester NHS Trust, UK.
W
W
Crasto
J
J
Jarvis
E
E
Hackett
V
V
Nayyar
P G
PG
McNally
M J
MJ
Davies
I G
IG
Lawrence
D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D016527:Drug Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D007333:Insulin Resistance / Q000502:physiology*; D009765:Obesity / Q000150:complications; D017060:Patient Satisfaction; D016896:Treatment Outcome; D015430:Weight Gain
D007004:Hypoglycemic Agents; D007328:Insulin